- Home
- PRLD vs LRFC Comparison
PRLD vs LRFC Comparison
Compare PRLD & LRFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- LRFC
- Stock Information
- Founded
- PRLD 2016
- LRFC 2013
- Country
- PRLD United States
- LRFC United States
- Employees
- PRLD N/A
- LRFC N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- LRFC Finance: Consumer Services
- Sector
- PRLD Health Care
- LRFC Finance
- Exchange
- PRLD Nasdaq
- LRFC Nasdaq
- Market Cap
- PRLD 73.7M
- LRFC N/A
- IPO Year
- PRLD 2020
- LRFC 2013
- Fundamental
- Price
- PRLD $0.82
- LRFC $22.00
- Analyst Decision
- PRLD Strong Buy
- LRFC
- Analyst Count
- PRLD 2
- LRFC 0
- Target Price
- PRLD $4.50
- LRFC N/A
- AVG Volume (30 Days)
- PRLD 201.7K
- LRFC 5.5K
- Earning Date
- PRLD 03-10-2025
- LRFC 03-13-2025
- Dividend Yield
- PRLD N/A
- LRFC 6.57%
- EPS Growth
- PRLD N/A
- LRFC N/A
- EPS
- PRLD N/A
- LRFC N/A
- Revenue
- PRLD $7,000,000.00
- LRFC $20,916,000.00
- Revenue This Year
- PRLD N/A
- LRFC N/A
- Revenue Next Year
- PRLD N/A
- LRFC N/A
- P/E Ratio
- PRLD N/A
- LRFC N/A
- Revenue Growth
- PRLD N/A
- LRFC 3.66
- 52 Week Low
- PRLD $0.63
- LRFC $20.65
- 52 Week High
- PRLD $6.80
- LRFC $26.00
- Technical
- Relative Strength Index (RSI)
- PRLD 56.29
- LRFC 30.40
- Support Level
- PRLD $0.71
- LRFC $21.70
- Resistance Level
- PRLD $0.76
- LRFC $22.36
- Average True Range (ATR)
- PRLD 0.07
- LRFC 0.59
- MACD
- PRLD 0.02
- LRFC -0.12
- Stochastic Oscillator
- PRLD 87.50
- LRFC 18.47
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.